4 European Projects Found
Searched on 125080 European Projects
FINISHED
TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases (TREATPOLYQ)
Start date: Mar 1, 2011, End date: Feb 28, 2015,
Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of mod ...
Read Project
17
Partners Participants
FINISHED
Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders (NEUROFGL)
Start date: Jan 1, 2012, End date: Dec 31, 2014,
Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and requires significant investment. NeuroFGL will contribut ...
Read Project
7
Partners Participants
FINISHED
A IAPP on the Role of NCAM in Stem Cell Differentiation (STEMCAM)
Start date: Sep 1, 2010, End date: Aug 31, 2014,
...ardial lineage, in comparison with embryonic stem cells. The project will take advantage of very unique and innovative pharmacological tools, the NCAM and growth factor mimetic peptides discovered by ENKAM. To achieve its aim STEMCAM will apply an interdisciplinary approach from cell biology (including innovative in vitro culture using bi- and three dimensional systems), immunocytochemistry, imagi ...
Read Project
6
Partners Participants
FINISHED
Synaptic mechanisms of memory loss: novel cell adhesion molecules as therapeutic targets (MemStick)
Start date: Feb 1, 2008, End date: Apr 30, 2011,
Memory loss is a central symptom in different diseases, and represents a significant social and economic burden for a large percentage of European citizens. The molecular and neurobiological bases of memory deficits are largely unknown and there are currently no drugs available that can markedly decelerate or prevent memory decline. To address this major problem, this project will investigate the ...
Read Project
